Francis Parnis - Concepedia

Author

Francis Parnis

Also Known As

C S Karapetis, F PARNIS, F Parnis, F X Parnis, F. Parnis, F. X. Parnis, F.X. Parnis, Francis PARNIS, Francis Parnis, Francis X Parnis

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

Centre for Cancer Biology Monash University Eastern Health The University of Adelaide Peter MacCallum Cancer Centre

About

Francis Parnis is an author at Centre for Cancer Biology specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	2.1K
2	Health Sciences	3	3	149
3	Cell Biology	2	2	24
4	Public Health	1	1	11
5	Diagnostic Sciences	1	1	51

Francis Parnis

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer Ian D. Davis, Andrew Martin, Martin R. Stockler, New England Journal of Medicine	2019	1.5K
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer Tomasz M. Beer, Eugene D. Kwon, Charles G. Drake, Journal of Clinical Oncology PharmacotherapyImmunotherapeuticsImmunotherapyMinimally Symptomatic PatientsPhase Iii Trial	2016	742
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin, NEJM Evidence UrologyGenitourinary CancerMedicineOlaparib ArmPolymerase Inhibitor Olaparib	2022	357
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial Fred Saad, Noel W. Clarke, Mototsugu Oya, The Lancet Oncology UrologyOncologyGenitourinary CancerMedicineAbiraterone Versus Placebo	2023	256
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial Christopher J. Sweeney, Andrew Martin, Martin R. Stockler, The Lancet Oncology UrologyOncologyGenitourinary CancerMedicineClinical Trials	2023	175
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial RobinKate Kelley, Baek‐Yeol Ryoo, Philippe Merle, ESMO Open	2020	82
Response to erlotinib in a patient with treatment refractory chordoma Nimit Singhal, Dusan Kotasek, Francis Parnis Anti-Cancer Drugs Tumor BiologySurgical OncologyTumoral PathologyDisease RefractoryMalignant Disease	2009	78
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP Martin R. Stockler, Andrew Martin, Ian D. Davis, Journal of Clinical Oncology	2021	57
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer Mustafa Khasraw, Nick Pavlakis, S. McCowatt, Annals of Oncology UrologyOncologyGenitourinary CancerMedicineHeparanase Inhibitor	2009	55
Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). Ian D. Davis, Andrew Martin, Robert Zielinski, Journal of Clinical Oncology Overall Survival OutcomesClinical EndpointPrognosisPharmacotherapyLogistic Analysis	2022	52

Page 1